Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Has Consensus Target Price of $11.50 According to Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have received an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $11.50.

A number of analysts recently weighed in on KPTI shares. HC Wainwright lowered shares of Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday, July 31st. Royal Bank Of Canada reissued an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. Wall Street Zen lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Robert W. Baird lowered Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Friday, July 31st. Finally, Piper Sandler dropped their target price on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a report on Friday, July 31st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth $623,000. Headlands Technologies LLC purchased a new position in Karyopharm Therapeutics in the 2nd quarter worth approximately $118,000. Bank of New York Mellon Corp purchased a new position in shares of Karyopharm Therapeutics in the second quarter worth $559,000. Avidity Partners Management LP lifted its holdings in shares of Karyopharm Therapeutics by 244.6% in the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock worth $2,583,000 after buying an additional 329,175 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in shares of Karyopharm Therapeutics by 4.1% during the first quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock worth $336,000 after acquiring an additional 2,399 shares during the last quarter. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Stock Down 1.1%

Shares of NASDAQ KPTI opened at $1.73 on Friday. The company has a market capitalization of $39.24 million, a PE ratio of -0.13 and a beta of 0.95. The stock’s 50 day moving average price is $2.98 and its 200-day moving average price is $6.56. Karyopharm Therapeutics has a twelve month low of $1.24 and a twelve month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The company had revenue of $33.43 million for the quarter, compared to the consensus estimate of $32.19 million. As a group, research analysts expect that Karyopharm Therapeutics will post -4.7 EPS for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on nuclear transport, particularly the role of exportin 1 (XPO1) in regulating the movement of proteins and RNA between a cell’s nucleus and cytoplasm.

Karyopharm’s primary product is selinexor, an oral selective inhibitor of XPO1. In the United States, selinexor is marketed as XPOVIO for certain patients with multiple myeloma and diffuse large B-cell lymphoma, in combination with specified therapies or under defined treatment circumstances.